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Colorectal cancer (CRC) is the third most prevalent cancer in both men and women,
and the second for cancer-related mortality, following lung cancer. Various types of
medicine or medicine combinations have been investigated as efﬁcient treatments.1,2
Nanomedicine offers noteworthy solutions and is considered as a magic bullet for
drug delivery in order to achieve maximum beneﬁt, while minimizing side effects and
improving drug efﬁcacy.3–6 Smart nanoparticulated drug delivery systems (DDSs)
(Figure 1) have made a great impact on the safe accumulation of anticancer drugs to
the designated region and the delivery of therapeutic agents based on external or
internal stimuli.5,7,8
5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades. It has been used as a ﬁrst line
antineoplastic agent in the treatment of several cancers, such as colorectal, breast,
head and neck, pancreas and stomach cancers. 5-FU is a water-soluble drug; hence,
it is administered intravenously.9,10 However, the appearance of drug resistance is
substantial limitation in the clinical usage of 5-FU. For instance, owing to its low
bioavailability, the cure rates of 5-FU for advanced CRC are less than 15%.
Moreover, 5-FU results in severe toxicological damage to the gastrointestinal (GI)
system and blood factors; and neurological, dermatological and cardiological
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Abstract: 5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades. It is considered a ﬁrst line antineoplastic
agent for the treatment of colorectal cancer. Unfortunately, chemotherapy with 5-FU has
several limitations, including its short half-life, high cytotoxicity and low bioavailability. In
order to overcome the drawbacks of 5-FU and enhance its therapeutic efﬁciency, many
scientiﬁc groups have focused on designing a new delivery system to successfully deliver 5FU to tumor sites. We provide a comprehensive review on different strategies to design
effective delivery systems, including nanoformulations, drug-conjugate formulations and
other strategies for the delivery of 5-FU to colorectal cancer. Furthermore, co-delivery of
5-FU with other therapeutics is discussed. This review critically highlights the recent
innovations in and literature on various types of carrier system for 5-FU.
Keywords: 5-ﬂuorouracil, drug delivery, colorectal cancer, nanomedicine, nanoparticles, codelivery
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Figure 1 Some nanoparticulate DDSs.

reactions.5,11 Thus, it is essential to develop promising
DDSs for 5-FU to achieve a better therapeutic effect
with fewer side effects. Another strategy to achieve good
results in the treatment of CRC is using ﬂuorouracil substitutes such as TAS-102, which can overcome the short
half-life and poor efﬁcacy of 5-FU and have a good
targeting effect.12
Although 5-FU is among the superior chemotherapeutic agents for CRC, there are several disadvantages,
including rapid metabolism, short half-life (around 10–20
minutes),13 low bioavailability, high cell toxicity and
inadequate selectivity for cancerous cells, all of which
limit the effectiveness of 5-FU in cancer chemotherapy.
Furthermore, oral formulations would result in seriously
adverse GI reactions. In order to surmount the disadvantages of 5-FU and enhance its chemotherapeutic efﬁcacy
in CRC, many research teams have focused on the development of new 5-FU delivery systems. With this method,
the cytotoxic effect of anticancer agents on healthy tissues
can be lessened by using speciﬁc DDSs7,14,15
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In this article, a comprehensive review of the literature,
considering contemporary articles on DDSs for 5-FU, is
presented. The mechanism of action and resistance to 5FU are also reviewed. Furthermore, potential strategies to
design novel DDSs for 5-FU are discussed. Finally, we
provide future outlooks on utilizing DDSs for 5-FU delivery to CRC.

Mechanism of Action and
Resistance to 5-FU
As an analogue of the nucleobase uracil, 5-FU can enter
cells via the same mechanism of facilitated transport as
uracil.16 Then, 5-FU is converted to ﬂuorodeoxyuridine
monophosphate (FdUMP), ﬂuorodeoxyuridine triphosphate (FdUTP) and ﬂuorouridine triphosphate (FUTP),
which are the active metabolites of 5-FU. RNA synthesis
and the operation of thymidylate synthase (TS) are interrupted by these metabolites (Figure 2).9 By this action, 5FU can ﬁght cancerous cells.
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Figure 2 Mechanism of action of 5-FU to inhibit thymidylate synthase.
Abbreviations: FdUMP, ﬂuorodeoxyuridine monophosphate; dUTP, deoxyuridine triphosphate; dTMP, deoxythymidine monophosphate; dTTP, deoxythymidine triphosphate methylene; THF, methylene tetrahydrofolate; DHF, dihydrofolate.

On the other hand, most of the provided 5-FU is
catabolized to dihydroﬂuorouracil (DHFU), which is an
inactive metabolite, by dihydropyrimidine dehydrogenase
(DPD). This is a rate-limiting enzyme for 5-FU catabolism
and is found to a great extent in liver and cancer cells.
Upregulation of DPD gene expression in CRC is associated with 5-FU resistance.17 Therefore, higher doses of
5-FU are needed in CRC with acquired drug resistance
(ADR).18

Potential Strategies to Enhance
Chemotherapy by 5-FU
One of the most important purposes of pharmaceutical
research is to discover and engineer new materials for
formulating 5-FU, in order to minimize side effects but
maximize clinical efﬁcacy.19,20 Different methods can be
used to construct drug carriers. For example, the use of a
core–shell structure, where the speciﬁc drug is in the core
of the DDS, can efﬁciently protect the drug from the
environment and prolong its circulation time.21 This

International Journal of Nanomedicine 2020:15

method results in physical entrapment of drug in the nanoformulation. In addition, using this strategy, passive accumulation of the DDS in the tumor environment can be
achieved, which is called the enhanced permeability and
retention effect.22,23 Furthermore, targeted delivery of the
drug can be achieved by several receptors overexpressed
on some tumor cells, such as asialoglycoproteins,24
transferrin,25 integrin receptors26,27 and folate.28
Another strategy used to make drug carrier systems
involves chemically binding the drug molecule to a polymer chain to create a polymer–drug conjugate. In this way,
burst release from the DDS is inhibited. This method has
advantages in increasing the solubility of the drug and
tunability of drug pharmacokinetics.22
In this section, we discuss three different types of
delivery system used in pharmaceutical research to deliver
5-FU successfully. First, nanotechnology-based 5-FU
delivery systems (Table 1) are discussed. Second, microparticulate delivery systems, and third, drug-conjugate
delivery of 5-FU are considered and discussed.
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Table 1 Different Nano-Delivery Systems of 5-FU
Main Format

Structure

Particle Size

Reference

Solid Lipid Nanoparticle

Stearic acid, lecithin, poloxamer 188

137±5.5 nm to 800±53.6
nm

32

Chitosan

CS-g-PCL
LMWC-4-bromomethyl-3-nitrobenzoic acid

61.4–108.6 nm
365 nm

33

CS-PAsp
CG5-FU-NPs and FCG5-FU-NPs

85–300 nm
31–33 nm

35

Fe3O4-encapsulating carbon nanospheres (TMMIPs)
Samarium ferrite (SmFeO3) nanoparticles coated with poly

150 nm
~50 nm

40

(methylmethacrylate)
CEINs–PEI–βCD–FA

˂100 nm

49

Molecularly Imprinted
Polymer

MIP-CS-g-PMMA
TMMIPs

130 nm
150 nm

39

Polymeric NP and MP

Poly(3-hydroxybutyrate-co-3 hydroxyhexanoate) (PHBHHx)
PLA and PLA-PEG

160 nm and 3 µm
294 nm and 283 nm

41

FA-PLGA

224±18 nm

42

Protein NP

Bovine serum albumin (BSA)

210 nm

43

Dendrimer

PEG-PAMAM
PDEA-mPEG-PAMAM (PPD)

270–307 nm
43.0 nm at pH 4.0,

45

Magnetic Nanocarrier

36

48

40

47

46

41.6 nm at pH 6.5 and
11.6 nm at pH 7.4
Liposome

Carbon Nanotube
Silica NP

Transferrin-conjugated liposome
Folate-PEG-DSPE

–
174 nm

52

Multi-walled CNTs
Epidermal growth factor–hollow mesoporous silica nanoparticles

–
120 nm and

56

53

18

pore size = 2.5 nm

Recruitment of Nano-Based Delivery
Systems
SLN-Based Delivery Systems
Solid lipid nanoparticles (SLNs), as a colloidal DDS, have
many advantages, including the ability to control the drug
release pattern and enhance drug stability, and possess a
high drug loading capacity.29–31
The incorporation of 5-FU into the shell of SLNs for
the treatment of Erlich’s tumor was investigated. The in
vitro release behavior of prepared SLNs was improved in
comparison with 5-FU alone. Moreover, the sodium carboxymethyl cellulose (NaCMC) gel matrix was used as a
suitable medium for SLN diffusion and release. SLN-treated mice exhibited improved treatment efﬁcacy in comparison to 5-FU-injected mice. As a result, SLNs could
enhance 5-FU or any other hydrophilic medicine through
the local route of administration.32
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Chitosan as a Polymeric Nanocarrier
CS-g-PCL
In one study, a series of chitosan-graft-poly(ε-caprolactone) micelles (CS-g-PCL) for 5-FU delivery was prepared. It was found that the properties of the micelles
were highly inﬂuenced by the length of the hydrophobic
chain of the copolymer. These copolymers showed controlled release behavior and interaction levels between
copolymers, and 5-FU was a determinant factor in tuning
the release rate. 5-FU-loaded micelles displayed adequate
biocompatibility and lower cytotoxicity in comparison to
free 5-FU as a result of the slow release behavior, yet they
were efﬁcient in killing cancerous cells.33
Low Molecular Weight Chitosan–5-FU Conjugate
A prodrug of 5-FU covalently conjugated to low molecular
weight chitosan (LMWC) with a photo-responsive linker
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(attachment of 5-FU with 4-bromomethyl-3-nitrobenzoic
acid, which is the cleavable linker) was also reported. The
linker was designed to be cleaved using UV light at 365
nm. The release of 5-FU was controlled via monitoring the
dose of the external stimulus. The conjugate polymer was
more water soluble and had improved cell penetration
ability (mean size less than 100 nm) in comparison to
LMWC, and produced hydrogel and DMSO-based gel.34
Chitosan–PAsp
Novel non-stoichiometric complex nanoparticles (NPs)
based on CS and polyaspartic acid (PAsp) were formulated. All of the in vitro and in vivo analyses of 5-FUloaded NPs exhibited CS-controlled and slow release of 5FU, in contrast to 5-FU solution. Furthermore, the area
under the curve (AUC) (an important parameter in pharmacokinetics) of the nano-based delivery systems was
increased.35
Folate-Tagged Chitosan Functionalized Gold NPs (CG-5FU-NPs and FCG-5-FU-NPs)
In a study by Akinyelu and Singh, 5-FU was loaded on
gold NPs, with CS and folate-tagged CS. This nanostructure had great colloidal stability and pH-dependent drug
release behavior. Moreover, the kinetics of drug release
was better ﬁtted to a zero-order mechanism. Also, the
anticancer effects of CG-5-FU-NPs and FCG-5-FU-NPs
were superior to those of free 5-FU in the MCF-7 and
HepG-2 cell lines. In addition, the study showed that FCG5-FU-NPs possessed higher cytotoxicity than CG-5-FUNPs in MCF-7 cells owing to the existence of folate
receptors on these cells.36
Surface Molecularly Imprinted Polymer of ChitosanGrafted Poly(Methyl Methacrylate) (MIP-CS-g-PMMA)
Molecular imprinting has been used as smart polymers
with particular recognition capacities for template
molecules.37,38 Zheng et al designed and prepared a
novel oral-based colon-targeted 5-FU delivery system
based on a molecularly imprinted method using CSPMMA as the matrix former for delivery of 5-FU
through microspheres. The in vitro release mechanism
was highly dependent on pH and time. 5-FU did not
release at pH 1, slow release was observed at pH 6.8
and fast release was achieved in the simulated colonic
ﬂuid (pH 7.4).39
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TMMIPs
A type of Fe3O4-encapsulating carbon nanosphere with a
shell of molecularly imprinted polymers, which are dually
responsive to temperature and magnetism (TMMIPs),
were produced by free radical polymerization. The synthesized nanospheres were used for controlled delivery of 5FU from aqueous media. These typical core–shell structures had a mean diameter of approximately 150 nm, and
the coating layer thickness was about 50 nm.40

PHBHHx
Several kinds of microparticles (MPs) and NPs based on
poly(3-hydroxybutyrate-co-3-hydroxyhexanoate)
(PHBHHx) were prepared by a double-emulsion solvent
evaporation technique. They were utilized as the carrier of
5-FU. The characterization showed that the synthesized
NPs and MPs had a spherical shape and sizes of approximately 160 nm for NPs and 3 µm for MPs. This study
revealed that cetyltrimethyl ammonium bromide (CTAB)
as the emulsiﬁer could enhance the drug loading content in
both NPs and MPs. The in vitro drug release behavior was
shown to be biphasic, with the initial burst release within 8
hours followed by a slow release rate throughout 24
hours.41

PLGA-Modiﬁed NPs
In a study by Wang et al, a novel conjugate of poly(lacticco-glycolic acid) (PLGA) NPs was prepared. These NPs
were conjugated with folic acid (FA), which is a suitable
ligand for receptors on HT-29 cancer cells. They used 1,3diaminopropane as a cross-linker. This cross-linker was
used to facilitate the conjugation of FA into PLGA-based
5-FU carriers. This fabrication had a great impact on
speciﬁc targeted DDSs for antineoplastic agents.42

BSA NPs (Protein-Based NPs)
Protein-based NPs have attracted growing attention as new
DDSs owing to their biodegradability and non-antigenicity. In a study conducted by Maghsoudi et al, 5-FUloaded BSA NPs were prepared by a phase separation
technique. Taguchi’s M16 design of experts was used in
order to investigate the effect of process variables on the
entrapment efﬁciency (%EE) of 5-FU. It was found that
pH had the most important effect on %EE as the response
parameter, and the amount of glutaraldehyde had the least
important inﬂuence. This 5-FU-loaded BSA had a sustained release behavior, as it was capable of releasing
drug based on zero kinetic release up to 20 hours.43
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Calcium Phosphate Nanoparticles (CaP NPs)

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 134.48.159.153 on 04-Jan-2022
For personal use only.

CaP NP have attracted great attention for anticancer drug
deliveryowing to their biodegradability in nature, controlled release pattern and considerable loading efﬁciency.
As a result, novel 5-FU-loaded CaP NPs (CaP–5-FU NPs)
were prepared by a reverse micelle method.44

PEG-PAMAM
In a study conducted by Bhadra et al, the application of
uncoated and PEGylated poly(amidoamine) (PAMAM)
dendrimers as 5-FU delivery systems was examined. 4.0
G PAMAM dendrimers were synthesized via Michael
addition and exhaustive amidation reactions. The core
was ethylenediamine and the propagating agent was
methylmethacrylate. In order to PEGylate the dendrimers,
carboxymethyl methoxy polyethylene glycol (MPEG5000),
which
was
previously
activated
by
N-hydroxysuccinimide (NHS), was used. This reaction
revealed enhancement of the drug loading content, controlled drug release behavior and reduced hemolytic toxicity. Also, PEGylation has been indicated to be advisable
for fabrication of PAMAM dendrimers in order to reduce
hematological disturbance and drug leakage. Moreover,
this modiﬁcation enhanced the drug loading capacity and
was determined to be suitable for depot administration of
5-FU delivery systems.45

PDEA-mPEG-PAMAM (PPD)
As a new fabrication, a core–shell structure by 4.0 G
PAMAM, parallel poly(2-(N,N-diethylamino)ethyl methacrylate (PDEA) chains and mPEG chains (as the shell) was
prepared. The PDEA chains were used owing to their pHresponsive behavior, and the PEG chains resulted in long
circulation in bloodstream to target the tumor region. This
polymer was used as the 5-FU carrier. As these nanocarriers were hydrophobic at pH 7.4 and hydrophilic at pH
6.5 (owing to the pH-responsive PDEA chains), NP sizes,
drug entrapment and release behavior were highly pH
dependent. The release of 5-FU from this system at pH
7.4 was faster than at pH 6.5. Therefore, it is a promising
system for antineoplastic drugs with high entrapment efﬁciency, pH-responsive release and tumor-targeting
capability.46

Poly(Lactic Acid) (PLA) and PLA-PEG
5-FU-loaded PLA or PLA-PEG NPs were prepared via an
emulsion solvent evaporation technique. The as-synthesized system could prolong 5-FU release but, surprisingly,
did not reduce 5-FU cytotoxicity in the HepG2 cell line.
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The researchers proved that all the pharmacokinetic parameters after a single oral administration in rats were
improved. For instance, 5-FU bioavailability was
enhanced four-fold in comparison to free 5-FU.
Consequently, PLA and PLA-PEG nanoparticles have
great potential as nanocarriers of 5-FU in oral delivery.47

Magnetic Nanoparticles
In a study by Hariharan et al, a series of 5-FU-loaded
samarium ferrite (SmFeO3) nanoparticles coated with
poly(methylmethacrylate) was prepared. The drug was
attached to the NPs by a host–guest complex with βcyclodextrin (βCD). The size was about 50 nm, and the
NPs showed a superparamagnetic behavior. In vitro cytotoxicity studies demonstrated the conservation of 5-FU
potency and activity.48

CEINs–PEI–βCD–FA
Carbon-encapsulated iron nanoparticles (CEINs) are used
as theranostic probes. In a study conducted by Kasprzak
et al, CEINs were chosen as the magnetic core of the DDS.
In order to modify the surface of CEINs, branched polyethyleneimine (PEI) was utilized. FA was utilized as the
targeting ligand, which is covalently attached to the
CEINs, while βCD was the host for 5-FU. The release
pattern of 5-FU was investigated at various pH levels. By
this examination, the highest release was seen at pH 9 and
the lowest at pH 4.7. So, this theranostic material has a
controlled release behavior and could be a promising DDS
in nanomedicine.49 In this kind of NP, the magnetic core
was used for diagnosis, and by delivering 5-FU to the
target site, this system was named a theranostic agent
(having both therapeutic and diagnosis pathways)
(Figure 3).

Transferrin-Conjugated Liposomes
Among the different vesicular systems, liposomes have
gained interest as a site-speciﬁc delivery system, owing
to their chemical and structural ﬂexibility, along with their
biocompatibility.50,51 In a study carried out by Soni et al,
5-FU-loaded transferrin-coupled liposomes were prepared
by the cast ﬁlm method. The in vivo results indicated a
selective uptake of the nanocarrier from the endothelial
cells of the brain. Approximately a 10-fold and 17-fold
increase in the uptake of 5-FU to the brain after the
entrapment by the liposomal system and transferrincoupled liposomes, respectively, was obtained,.52
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Figure 3 Synthesis of CEINs–PEI–5-FU–βCD–FA nanotheranostic agents.
Note: Copyright © 2018 Chemistry Select. Reproduce from Kasprzak A, Gunka K, Fronczak M, Bystrzejewski M, Poplawska M. Folic acid-navigated and
β-cyclodextrin-decorated carbon-encapsulated iron nanoparticles as the nanotheranostic platform for controlled release of 5-ﬂuorouracil. Chemistry Select. 2018;3
(38):10821–10830.49
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Folate–PEG-DSPE
In a study conducted by Handali et al, optimization of a
preparation of 5-FU-loaded phosphatidyl choline (PC)
liposome was evaluated. FA was used as the targeting
ligand for the surface receptors of HT-29, Caco-2 and
MCF-7 cell lines. According to the results, the amount of
PC was a signiﬁcant variable in optimizing particle size
and entrapment efﬁciency. Furthermore, in vitro cytotoxicity assays demonstrated that folate-conjugated liposomes
had superior antitumor activity compared to the bare
liposomes.53

OFZG
A phospholipase A2-sensitive amphiphilic prodrug, 1-Ooctadecyl-2-(5-ﬂuorouracil)-N-acetyl-3-zidovudine-phosphorylglycerol (OFZG), was prepared and utilized as the
nanoassembly during the injection of a mixture of Tween
80/cholesterol/OFZG (0.1:1:2 mol/mol/mol) in water.
Secretory phospholipase A2, which cleaves ester, is overexpressed in several types of cancer cells. The nanoassemblies exhibited improved anticancer activity compared to
5-FU in HCT116, HT-28 and COLO205 cell lines. The
distribution of OFZG after intravenous administration was
mainly in the kidney, spleen, lung and liver; it also exhibited rapid elimination.54

Multi-Walled Carbon Nanotubes (MWCNTs)
Carbon nanotubes (CNTs), as a developing type of nanomaterial, have been established as vehicles for gene and
drug delivery.55 A group of researchers applied multiwalled carbon nanotubes (MWCNTs) to improve the cytotoxic and antitumoral effects of 5-FU. The drug was physically adsorbed on to MWCNTs, and the effect of drug
both in vitro and in vivo was signiﬁcantly improved. This
study suggested that by using MWCNTs as carriers for
antineoplastic drug delivery, not only would the efﬁcacy
be improved, but also the chances of resistance to cancer
cells would be considerably diminished.56

Silica Nanoparticles (EGF-HMSNs)
Silica NPs provide unique properties as a drug delivery
vehicle, including excellent stability and biocompatibility,
along with a highly ordered structure of pores with uniform size.57 In order to overwhelm ADR in CRC, a series
of hollow mesoporous silica nanoparticles (HMSNs) conjugated with epidermal growth factor (EGF) was recruited
as nanovehicles for 5-FU delivery to the SW480/ADR cell
line, which is a CRC cell line with overexpression of EGF
receptors. This type of nanocarrier was speciﬁcally
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internalized in the cells via receptor-mediated endocytosis
and could successfully facilitate endosomal escape; by this
method, ADR could be overcome in this cell line, resulting
in cell death at the S phase of the cell cycle.18

MAA–co-IA Hydrogel
A new nanohydrogel based on methacrylic acid (MAA)
and itaconic acid (IA), with ethylene glycol dimethacrylate
(EGDMA) as a cross-linker, was synthesized for oral
administration of 5-FU and leucovorin calcium (LV) to
reach to the target site of the colon. This combinatorial
DDS had a pH-responsive property to release the cargo at
the pH of the colon (pH 7.4), but remain intact at acidic
pH. This property was due to the existence of carboxylic
acid groups in the structure of this delivery system, which
were able to ionize at higher pH. The polymeric network is
prone to swelling in this condition, and faster release of
the loaded drug would be expected as a consequence of
polymer swelling at pH 7.4. The release was better ﬁtted to
ﬁrst order kinetics.58

Non-Nano-Based Delivery Systems for 5FU
Eudragit P-4581F/RS100 Microspheres
A colon-targeted MP, as an oral DDS, was prepared via an
easy oil-in-water emulsiﬁcation process. Eudragit
P-4581F, which is a pH-sensitive polymer, and Eudragit
RS100, which prolongs drug release, were used in the
formulation. This type of microsphere provided a colonspeciﬁc delivery system that permits release of the cargo at
pH 7.4, and prolonged release at the speciﬁc site would be
expected owing to the presence of Eudragit RS100. This
formulation would be a potential candidate for oral delivery of 5-FU.59

Eudragit S100 Electrospun Fibers
Various series of 5-FU-loaded Eudragit S100 ﬁbers were
prepared by electrospinning to fabricate a pH-sensitive
oral delivery system. However, after characterization analyses, it was revealed that a very signiﬁcant amount of 5FU was immediately released in stomach-mimicking
media (pH 1.0) owing to the low molecular weight of 5FU, which allows its diffusion through the ﬁbers. Also, the
loss of ﬁber integrity was another proposed reason for 5FU escaping at the initial time of release.60

Floating Bioadhesive Tablet (FBT)
To target gastric cancer and diminish the dose and side
effects, a series of FBTs of 5-FU was prepared. The tablets
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were made by a direct compression process. Hydroxyl
propyl methyl cellulose (HPMC) was used to sustain the
drug release and carbopol-971P, guar gum and sodium
alginate were employed for their bioadhesive properties.
This formulation could be successful as a gastric-targeted
DDS.61

PVC/PEG Polymeric Film
In a study by Khalaf et al, a polymeric ﬁlm based on
polyvinyl chloride (PVC), PEG and starch cellulose
acetate (SCA) was prepared. Trioctyltrimellitate, poly
(MA-alt-NVP) (TOTM) was used as a plasticizer. It
was suggested that a PVC/PEG/TOTM blend with a
ratio of 10:90:5 had good mechanical properties.
Moreover, the drug (5-FU) release pattern depended on
the pH of the medium. In this regard, a sustained release
pattern was observed, but a faster and higher release
was detected at higher pH. The cytotoxic assay indicated that release of 5-FU from the ﬁlm had a sustained
behavior in human liver cells.62

Matrix Tablet with Pectin-Based Coat
In order to obtain a colon-targeted 5-FU tablet, a microbially responsive pectin-based matrix tablet of 5-FU was
prepared. Then, Eudragit S100 was used as a coating agent
to restrict the release of 5-FU to the colon region. As a
result, the systemic side effects were reduced and efﬁcacy
was improved.63

Applying Drug Conjugates for 5-FU
Delivery
Poly(MA-alt-NVP)
A water-soluble and alternating copolymer of poly(maleic
anhydride-alt-N-vinyl pyrrolidonepoly(MA-alt-NVP) was
synthesized via a charge transfer complex (CTC). The
characterization of the copolymer was conﬁrmed by attenuated total reﬂection–Fourier transform infrared, nuclear
magnetic resonance, high-resolution Raman and X-ray
diffraction spectroscopy. Then, conjugation of 5-FU to
the copolymer was demonstrated by the aforementioned
analyses.64 The results conﬁrmed the successful copolymerization, and this copolymer could be used as a carrier
for 5-FU to deliver this anticancer drug.

Poly(Ethylene Oxide)-b-Poly(n-Butyl Methacrylateco-4-Methyl-[7-(Methacryloyl)Oxyethyloxy]
Coumarin)) (PEO-b-P(BMA-co-CMA))
A series of block copolymers functionalized by coumarin
was synthesized according to the atom transfer radical polymerization (ATRP) method. The drug–micelle conjugates
were prepared by covalent bonding of 5-FU to the coumarin
under UV radiation. Moreover, the drug release study was
conducted under UV radiation (approximately 254 nm), and
the results demonstrated the controlled release of 5-FU from
the conjugates. Therefore, a photoresponsive biocompatible
5-FU delivery system was prepared that would be a potential
candidate for delivery of other antineoplastic agents.65

Table 2 Combinational Delivery System Containing 5-FU
Drug Used for

Type of Delivery System

Advantages/Improvement of Application

Reference

PFL/PPLL hydrogel

Induces cell cycle arrest

69

Co-Delivery
Metformin

Increases cytotoxicity of 5-FU
Leucovorin Calcium

MAA-IA-EGDMA hydrogel

Synergizes the cytotoxicity activity of 5-FU

58

As-miR-21

PAMAM dendrimer

Represses cell growth

70

Induces apoptosis
Increases cytotoxicity of 5-FU
Decreases adverse side reactions by targeting miR-21 overexpressing tumors
LY294002

PEGylated nanoliposome

Enhances the sensitivity of tumor cells against 5-FU
Results in higher cytotoxicity

71

CD-siRNA

LDH NPs

Overwhelms the drug resistance
Improves cytotoxicity

72
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T22-GFP-H6-FdU
In a study conducted by Céspedes et al, the active metabolite of 5-FU (ﬂoxuridine, FdU) was delivered to the
CRC tumor. This cytotoxic agent was used to treat liver
metastases of CRC. In this study, a nanoconjugate containing a fusion protein (the peptide T22 as a CXCR4 ligand, a
green ﬂuorescent protein and a histidine tail) was bound to
FdU. This protein-based nanoconjugate selectively internalized and destroyed CXCR4+ CRC tumor cells and
hence achieved a targeted DDS.66

Combination Delivery of 5-FU
Combinational chemotherapy is attracting more attention in
comparison to single chemotherapy regimens. Combinatorial
strategies in cancer treatment create a synergetic effect and,
therefore, can enhances therapeutic efﬁciency.67 Using combinational therapeutics could be very effective owing to their
enhanced curative efﬁcacy in many diseases, such as malignant tumors.68 Table 2 presents some combination delivery
systems discussed in this article.

Metformin
A nanohydrogel based on reactive aldehyde-functionalized
4-arm PEG (PFA) and four-arm PEG-b-poly(L-lysine)
(PPLL) was prepared via Schiff’s base reaction. This nanocarrier could simultaneously deliver metformin and 5-FU to
colon 26 (C26) cell lines for improvement of antineoplastic
activity and to overcome side effects. The combination treatment of 5-FU and metformin could induce cell cycle arrest
and apoptosis, while subsequently increasing cytotoxicity
both in vitro and in vivo. The release of both drugs was
achieved in a controlled manner and pH-dependent pattern.
As a result, this injectable hydrogel could perform successfully in the treatment of CRC.69

Leucovorin Calcium
A novel hydrogel based on MAA and IA, with EGDMA as
a cross-linker, was synthesized for oral administration of
both 5-FU and LV to reach to the target site of the colon.
LC administration with 5-FU was able to synergistically
increase the cytotoxic activity and potency of 5-FU, as
well as enhancing the therapeutic index.58

As-miR-21
MicroRNAs (miRNAs) have been proven to be deregulated in various types of tumor cell. miR-21, as a pipeline
in glioblastoma cells, can repress cell growth, induce cell
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apoptosis and lead to cell cycle arrest. Therefore, it can
increase the therapeutic response of neoplastic drugs. In a
study conducted by Ren et al, PAMAM dendrimer was
used as a carrier for dual delivery of antisensemicroRNA21 (as-miR-21) oligonucleotide and 5-FU to
accomplish the best result regarding cytotoxic efﬁcacy.
The MTT assay was performed in glioma cells (U251)
and showed a dramatic increase in cytotoxicity.
Therefore, this article suggested that co-delivery of asmiR-21 and 5-FU could have signiﬁcant clinical outcomes
in the cure of miR-21-overexpressing tumor cells.70

Autophagy Inhibitor (LY294002)
In this study, 5-FU and LY294002 were successfully
loaded in PEGylated nanoliposomes to target esophageal
squamous cell carcinoma (ESCC). This combinatorial
drug delivery could lead to higher cytotoxic efﬁcacy compared to single drug therapy. Also, the faster release of LY
compared to 5-FU could result in the inhibition of autophagy, which enhanced the sensitivity of tumor cells to 5FU and induced a greater extent of apoptosis.71

CD-siRNA
Layered double hydroxide (LDH) NPs were employed as a
vehicle for the co-delivery of 5-FU and Allstars Cell Death
siRNA (CD-siRNA) to enhance cancer treatment. The
LDH intercalated 5-FU into its interlayer space and also
loaded siRNA on the external parts of LDH NPs. This type
of NP has been indicated to be effective as an intracellular
delivery system. Moreover, the combination of the antineoplastic drug 5-FU and CD-siRNA could signiﬁcantly
improve cytotoxicity in HCT-116, U2OS and MCF-7 cell
lines, in comparison to single therapy, owing to the simultaneous mitochondrial damage process. Consequently, the
approach of co-delivery of siRNA and 5-FU by LDH NPs
could be promising in overwhelming the drug resistance
and improving cancer treatment.72

Future Outlook and Conclusion
The application of novel DDSs in the ﬁeld of pharmaceutical
sciences has revolutionized healthcare systems, because carrier-based advanced DDSs can signiﬁcantly reduce the
adverse effects of drugs and improve the drug efﬁcacy. In
this review, nano-based delivery systems of 5-FU were highlighted. This type of DDS has the potential to enhance the
physicochemical aspects of drug characteristics and can effectively target 5-FU to the cancerous region. Moreover, today
the ﬁeld of nanomedicine is taking the lead for personalized
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medicine.73 So, it is important to use this kind of novel
technology to carry the drugs. All types of nanocarrier, including CNTs, liposomes, polymeric NPs, silica NPs, dendrimers
and micelles, have advantages over conventional delivery
systems and, in most cases, outweigh the disadvantages.
Furthermore, combining therapeutic agents with 5-FU
to enhance therapeutic efﬁcacy is another beneﬁcial ability
of novel delivery systems for the treatment of CRC. This
strategy can also enhance the sensitivity of tumor cells to
5-FU and overcome drug resistance.
Another strategy is the application of stimuli-responsive nanocarriers to achieve passive targeting delivery. The
physical/chemical and internal/external stimuli provide
precise control of 5-FU release and, therefore, can reduce
severe side effects following premature release.4
We believe that in the future, nanomedicine-based codelivery DDSs will be more promising than conventional
drugs to cure cancers, but more attempts must be completed to enhance the pharmacokinetic aspects of this type
of DDS and successfully translating to the clinic.

Entezar-Almahdi et al

methacrylic acid; IA, itaconic acid; EGDMA, ethylene glycol dimethacrylate; LV, leucovorin calcium; FBT, ﬂoating
bioadhesive tablet; HPMC, hydroxyl propyl methyl cellulose; PVC, polyvinyl chloride; SCA, starch cellulose acetate;
TOTM, trioctyltrimellitate; poly(MA-alt-NVP), poly(maleic
anhydride-alt-N-vinyl pyrrolidone); CTC, charge transfer
complex; PEO-b-P(BMA-co-CMA), poly(ethylene oxide)b-poly(n-butyl methacrylate-co-4-methyl-[7-(methacryloyl)
oxyethyloxy]coumarin)); ATRP, atom transfer radical polymerization; as-miR-21, antisense-microRNA21; ESCC, esophageal squamous cell carcinoma; CD-siRNA, Allstars Cell
Death siRNA; LDH, layered double hydroxide.
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